# X4 Pharmaceuticals, Inc: Form 8-K, filed Oct 8, 2026

- Company: [X4 Pharmaceuticals, Inc](/companies/xfor.md) (CIK 1501697)
- Form: 8-K
- Filed: 2026-10-08
- Accepted by EDGAR: Oct 8, 2026, 17:23 ET
- Period: 2026-10-07
- Accession: 0001501697-26-000081
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1501697/000150169726000081/xfor-20261007.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1501697/000150169726000081/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 1.02: Termination of a material agreement
- Item 2.03: New direct financial obligation
- Item 3.02: Unregistered sale of equity
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1501697/000150169726000081/xfor-20261007.htm

Filed Oct 8, 2026.
Source: SEC EDGAR, the filing index for accession 0001501697-26-000081. Last ingested by Listed: Nov 15, 2026, 04:16 ET. No prices; not investment advice.
